| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.22 | 0.2 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.072 | 0.2 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.21 | 0.2 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.077 | 0.2 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.22 | 0.2 |
| mRNA | AP-24534 | FIMM | pan-cancer | AAC | 0.21 | 0.2 |